Drugs / RUGECITIDE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04840914 | Jun 2021 → May 2024 | congestive heart failure | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04352114 | Jun 2020 → Jan 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RUGECITIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068616 ↗ |
| Known as | LY3461767 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04840914 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL6068616 ↗ |
| Route | Subcutaneous | “Administered SC.” NCT04352114 ↗ |